ERBB2 and breast carcinoma: It should be noted that the glycolysis signature was associated with poor prognoses in luminal and basal-like breast cancer patients, but not in the HER2 subtype, indicating that HER2-enriched breast cancer may have distinct molecular characteristics which are independent of YBX1 or glycolysis.